AU2014305792C1 - Tricyclic benzoxaborole compounds and uses thereof - Google Patents
Tricyclic benzoxaborole compounds and uses thereof Download PDFInfo
- Publication number
- AU2014305792C1 AU2014305792C1 AU2014305792A AU2014305792A AU2014305792C1 AU 2014305792 C1 AU2014305792 C1 AU 2014305792C1 AU 2014305792 A AU2014305792 A AU 2014305792A AU 2014305792 A AU2014305792 A AU 2014305792A AU 2014305792 C1 AU2014305792 C1 AU 2014305792C1
- Authority
- AU
- Australia
- Prior art keywords
- mycobacterium
- compound
- pharmaceutically acceptable
- tuberculosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*)(CO1)OB2O[C@@](CN)c3c2c1ccc3* Chemical compound *C(*)(CO1)OB2O[C@@](CN)c3c2c1ccc3* 0.000 description 5
- NNGNOBBIKFFDEA-ZCFIWIBFSA-N NC[C@H](c(c1c(cc2)O)c2Br)OB1O Chemical compound NC[C@H](c(c1c(cc2)O)c2Br)OB1O NNGNOBBIKFFDEA-ZCFIWIBFSA-N 0.000 description 2
- CLGYZFTZLYKYGE-ZCFIWIBFSA-N NC[C@H](c(c1c(cc2)O)c2Cl)OB1O Chemical compound NC[C@H](c(c1c(cc2)O)c2Cl)OB1O CLGYZFTZLYKYGE-ZCFIWIBFSA-N 0.000 description 2
- FATHSKDRFVSAJJ-UHFFFAOYSA-N CC(C)(C)OC(NCC(c(c1c(cc2)O)c2Br)OB1O)=O Chemical compound CC(C)(C)OC(NCC(c(c1c(cc2)O)c2Br)OB1O)=O FATHSKDRFVSAJJ-UHFFFAOYSA-N 0.000 description 1
- VZZJZKYHYSGWMK-UHFFFAOYSA-N CC(C)(C)OC(NCC1OB2OC(C)(CO)COc(cc3)c2c1c3Br)=O Chemical compound CC(C)(C)OC(NCC1OB2OC(C)(CO)COc(cc3)c2c1c3Br)=O VZZJZKYHYSGWMK-UHFFFAOYSA-N 0.000 description 1
- UHFQBHZQYVITQE-SNVBAGLBSA-N CC(C)(C)OC(NC[C@H](c1cccc(O)c11)OB1O)=O Chemical compound CC(C)(C)OC(NC[C@H](c1cccc(O)c11)OB1O)=O UHFQBHZQYVITQE-SNVBAGLBSA-N 0.000 description 1
- OAGXCFZRRVEFIB-UHFFFAOYSA-N CC(C)(CO1)OB2OC(CN)c3c2c1ccc3 Chemical compound CC(C)(CO1)OB2OC(CN)c3c2c1ccc3 OAGXCFZRRVEFIB-UHFFFAOYSA-N 0.000 description 1
- AEZWTOOSBQYMPG-UHFFFAOYSA-N CCC(c(c1c(cc2)O)c2Br)OB1OC Chemical compound CCC(c(c1c(cc2)O)c2Br)OB1OC AEZWTOOSBQYMPG-UHFFFAOYSA-N 0.000 description 1
- VLVUMBJSODXRME-UHFFFAOYSA-N CCC(c1c23)OB2OC(C)(C)COc3ccc1Br Chemical compound CCC(c1c23)OB2OC(C)(C)COc3ccc1Br VLVUMBJSODXRME-UHFFFAOYSA-N 0.000 description 1
- UIDRVQZKXPITMF-SSDOTTSWSA-N CC[C@H](c1c2c(O)ccc1Cl)OB2O Chemical compound CC[C@H](c1c2c(O)ccc1Cl)OB2O UIDRVQZKXPITMF-SSDOTTSWSA-N 0.000 description 1
- JNIRWUYWMTVDGB-HXJPCDODSA-N C[C@@](CO)(CO1)OB2OC(/C=C/N)c3c2c1ccc3Br Chemical compound C[C@@](CO)(CO1)OB2OC(/C=C/N)c3c2c1ccc3Br JNIRWUYWMTVDGB-HXJPCDODSA-N 0.000 description 1
- HFXFHBAFGFICLN-CYBMUJFWSA-N C[C@H](c1cccc(OCCOCc2ccccc2)c11)OB1O Chemical compound C[C@H](c1cccc(OCCOCc2ccccc2)c11)OB1O HFXFHBAFGFICLN-CYBMUJFWSA-N 0.000 description 1
- RZZXJVYOGAMZGS-SKDRFNHKSA-N C[C@](CO)(COc(cc1)c23)OB2O[C@H](CN)c3c1Br Chemical compound C[C@](CO)(COc(cc1)c23)OB2O[C@H](CN)c3c1Br RZZXJVYOGAMZGS-SKDRFNHKSA-N 0.000 description 1
- NNGNOBBIKFFDEA-UHFFFAOYSA-N NCC(c(c1c(cc2)O)c2Br)OB1O Chemical compound NCC(c(c1c(cc2)O)c2Br)OB1O NNGNOBBIKFFDEA-UHFFFAOYSA-N 0.000 description 1
- DIDUSPQIIVEBOF-UHFFFAOYSA-N O=Cc1cccc(OCCOCc2ccccc2)c1 Chemical compound O=Cc1cccc(OCCOCc2ccccc2)c1 DIDUSPQIIVEBOF-UHFFFAOYSA-N 0.000 description 1
- NLDFCOFDOLBIAD-UHFFFAOYSA-N OB(c1c(cc2)O)OC(CN=O)c1c2Cl Chemical compound OB(c1c(cc2)O)OC(CN=O)c1c2Cl NLDFCOFDOLBIAD-UHFFFAOYSA-N 0.000 description 1
- IAVREABSGIHHMO-UHFFFAOYSA-N Oc1cc(C=O)ccc1 Chemical compound Oc1cc(C=O)ccc1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 1
- UTEHYABQAUVXFJ-UHFFFAOYSA-N [O-][N+](CC1OB2OCCOc3c2c1ccc3)=O Chemical compound [O-][N+](CC1OB2OCCOc3c2c1ccc3)=O UTEHYABQAUVXFJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017210567A AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864496P | 2013-08-09 | 2013-08-09 | |
| US61/864,496 | 2013-08-09 | ||
| US201361918976P | 2013-12-20 | 2013-12-20 | |
| US61/918,976 | 2013-12-20 | ||
| PCT/US2014/050370 WO2015021396A2 (en) | 2013-08-09 | 2014-08-08 | Tricyclic benzoxaborole compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017210567A Division AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014305792A1 AU2014305792A1 (en) | 2016-03-10 |
| AU2014305792B2 AU2014305792B2 (en) | 2017-05-04 |
| AU2014305792C1 true AU2014305792C1 (en) | 2018-07-05 |
Family
ID=52462052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014305792A Active AU2014305792C1 (en) | 2013-08-09 | 2014-08-08 | Tricyclic benzoxaborole compounds and uses thereof |
| AU2017210567A Active AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017210567A Active AU2017210567B2 (en) | 2013-08-09 | 2017-08-03 | Tricyclic benzoxaborole compounds and uses thereof |
Country Status (35)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR094961A1 (es) * | 2013-03-15 | 2015-09-09 | Lilly Co Eli | 1-hidroxi-benzooxaboroles como agentes antiparasitarios |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| US20160251380A1 (en) | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
| CN106459097A (zh) | 2014-07-01 | 2017-02-22 | 第三共株式会社 | 作为抗菌剂的三环苯并氧杂硼杂环戊烯类 |
| MA41495A (fr) * | 2015-02-12 | 2017-12-19 | Anacor Pharmaceuticals Inc | Composés benzoxaborole et leurs utilisations |
| PE20190119A1 (es) | 2016-05-12 | 2019-01-17 | Anacor Pharmaceuticals Inc | Esteres de oxaborol y sus usos |
| CN109387594B (zh) * | 2017-08-08 | 2021-01-19 | 武汉武药科技有限公司 | 一种分离和分析贝达喹啉光学异构体的方法 |
| ES2949908T3 (es) * | 2018-01-09 | 2023-10-03 | Halcyon Labs Private Ltd | Proceso para la preparación de Crisaborol y sus intermedios |
| EP4164645A4 (en) * | 2020-06-15 | 2024-07-10 | The Global Alliance for TB Drug Development, Inc. | COMBINED ANTIBACTERIAL COMPOSITION AND ANTIBACTERIAL THERAPY METHOD |
| CN111606850B (zh) * | 2020-07-07 | 2023-07-25 | 安徽贝克生物制药有限公司 | 贝达喹啉及其中间体的制备方法 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| CA3239097A1 (en) | 2022-06-23 | 2023-12-28 | Shanghai Micurx Pharmaceutical Co., Ltd. | Prodrugs of boron compounds and their use in treating bacterial infections |
| JP2025520237A (ja) * | 2022-06-23 | 2025-07-03 | ミクウルク ファーマシューティカルズ， インコーポレイテッド | ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物 |
| WO2024208907A1 (en) | 2023-04-05 | 2024-10-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Synthesis of 3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3h)-ol |
| CN117379430B (zh) * | 2023-10-11 | 2026-07-21 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165411A1 (en) * | 2011-12-22 | 2013-06-27 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998024753A1 (en) | 1996-12-02 | 1998-06-11 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same |
| US7446236B2 (en) | 2002-12-02 | 2008-11-04 | Solvias Ag | Catalytic hydrogenation of carbon-heteroatom double bonds |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| JP5084717B2 (ja) | 2005-03-08 | 2012-11-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | キラル・ビスオキサゾリン触媒 |
| CN101505603A (zh) * | 2005-12-30 | 2009-08-12 | 安纳考尔医药公司 | 含硼的小分子 |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) * | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| SG172040A1 (en) | 2008-12-17 | 2011-07-28 | Anacor Pharmaceuticals Inc | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| AU2011237681B2 (en) * | 2010-04-07 | 2015-01-22 | Glaxosmithkline Llc | Process for preparing benzoxaboroles |
| DK2613788T3 (en) * | 2010-09-07 | 2017-08-07 | Anacor Pharmaceuticals Inc | BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| US20160251380A1 (en) | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
| MA41495A (fr) * | 2015-02-12 | 2017-12-19 | Anacor Pharmaceuticals Inc | Composés benzoxaborole et leurs utilisations |
-
2014
- 2014-08-08 US US14/387,384 patent/US20160251380A1/en not_active Abandoned
- 2014-08-08 HU HUE14834292A patent/HUE057365T2/hu unknown
- 2014-08-08 MY MYPI2016700458A patent/MY175823A/en unknown
- 2014-08-08 MX MX2016001732A patent/MX375556B/es active IP Right Grant
- 2014-08-08 UA UAA201600796A patent/UA116908C2/uk unknown
- 2014-08-08 KR KR1020167006314A patent/KR102093783B1/ko active Active
- 2014-08-08 NZ NZ716350A patent/NZ716350A/en unknown
- 2014-08-08 ES ES14834292T patent/ES2905413T3/es active Active
- 2014-08-08 HR HRP20220384TT patent/HRP20220384T1/hr unknown
- 2014-08-08 AU AU2014305792A patent/AU2014305792C1/en active Active
- 2014-08-08 BR BR112016002651-9A patent/BR112016002651B1/pt active IP Right Grant
- 2014-08-08 EP EP14834292.6A patent/EP3030519B1/en active Active
- 2014-08-08 SG SG10201914073PA patent/SG10201914073PA/en unknown
- 2014-08-08 PE PE2016000234A patent/PE20160752A1/es unknown
- 2014-08-08 AP AP2016009046A patent/AP2016009046A0/en unknown
- 2014-08-08 EP EP21214787.0A patent/EP4029870A1/en not_active Withdrawn
- 2014-08-08 DK DK14834292.6T patent/DK3030519T3/da active
- 2014-08-08 PT PT148342926T patent/PT3030519T/pt unknown
- 2014-08-08 WO PCT/US2014/050370 patent/WO2015021396A2/en not_active Ceased
- 2014-08-08 JP JP2016533471A patent/JP6499175B2/ja active Active
- 2014-08-08 RS RS20220108A patent/RS62887B1/sr unknown
- 2014-08-08 EA EA201690135A patent/EA032844B1/ru unknown
- 2014-08-08 LT LTEPPCT/US2014/050370T patent/LT3030519T/lt unknown
- 2014-08-08 SI SI201431939T patent/SI3030519T1/sl unknown
- 2014-08-08 PL PL14834292T patent/PL3030519T3/pl unknown
- 2014-08-08 CN CN201480049562.3A patent/CN105492388B/zh active Active
- 2014-08-08 CN CN201811396796.1A patent/CN110003253B/zh active Active
- 2014-08-08 SG SG11201600787PA patent/SG11201600787PA/en unknown
- 2014-08-08 SM SM20220113T patent/SMT202200113T1/it unknown
- 2014-08-08 CA CA2919888A patent/CA2919888C/en active Active
-
2016
- 2016-01-28 IL IL243874A patent/IL243874B/en active IP Right Grant
- 2016-02-03 PH PH12016500234A patent/PH12016500234B1/en unknown
- 2016-02-04 ZA ZA2016/00792A patent/ZA201600792B/en unknown
- 2016-02-07 SA SA516370551A patent/SA516370551B1/ar unknown
- 2016-02-08 CL CL2016000313A patent/CL2016000313A1/es unknown
- 2016-02-09 DO DO2016000045A patent/DOP2016000045A/es unknown
- 2016-02-09 CR CR20160064A patent/CR20160064A/es unknown
-
2017
- 2017-08-03 AU AU2017210567A patent/AU2017210567B2/en active Active
- 2017-10-24 US US15/792,251 patent/US10308668B2/en active Active
-
2019
- 2019-03-14 JP JP2019046582A patent/JP6764970B2/ja active Active
- 2019-04-16 US US16/385,547 patent/US10526352B2/en active Active
- 2019-11-26 US US16/695,253 patent/US10858376B2/en active Active
-
2020
- 2020-11-04 US US17/089,058 patent/US20210053999A1/en not_active Abandoned
-
2022
- 2022-03-01 CY CY20221100169T patent/CY1125030T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130165411A1 (en) * | 2011-12-22 | 2013-06-27 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017210567B2 (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| US11214582B2 (en) | 4-substituted benzoxaborole compounds and uses thereof | |
| HK1219939B (en) | Tricyclic benzoxaborole compounds and uses thereof | |
| OA17674A (en) | Tricyclic benzoxaborole compounds and uses thereof. | |
| HK1240232A1 (en) | 4-substituted benzoxaborole compounds and uses thereof | |
| HK1240232B (en) | 4-substituted benzoxaborole compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 AUG 2017 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 AUG 2017 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2018 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2018 |
|
| HB | Alteration of name in register |
Owner name: ANACOR PHARMACEUTICALS, LLC. Free format text: FORMER NAME(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ANACOR PHARMACEUTICALS, INC. Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED Free format text: FORMER NAME(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; ANACOR PHARMACEUTICALS, INC. |